35,357 Shares in Progyny, Inc. $PGNY Acquired by Man Group plc

Man Group plc acquired a new stake in Progyny, Inc. (NASDAQ:PGNY) in the 2nd quarter, Holdings Channel reports. The firm acquired 35,357 shares of the company’s stock, valued at approximately $1,019,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of PGNY. Caitong International Asset Management Co. Ltd purchased a new stake in Progyny during the fourth quarter worth $25,000. Hantz Financial Services Inc. increased its position in shares of Progyny by 79.4% in the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after buying an additional 742 shares in the last quarter. Quarry LP increased its position in shares of Progyny by 2,004.1% in the third quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after buying an additional 3,427 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in shares of Progyny during the 2nd quarter worth $77,000. Finally, New Age Alpha Advisors LLC purchased a new stake in shares of Progyny in the 4th quarter worth about $94,000. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Trading Up 2.5%

NASDAQ:PGNY opened at $26.29 on Thursday. The firm has a market cap of $2.02 billion, a price-to-earnings ratio of 28.58, a price-to-earnings-growth ratio of 1.77 and a beta of 0.99. The company’s 50-day moving average is $29.03 and its two-hundred day moving average is $23.74. Progyny, Inc. has a 12-month low of $16.10 and a 12-month high of $33.06.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. The company had revenue of $350.51 million for the quarter, compared to analysts’ expectations of $349.05 million. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period last year, the company earned $0.19 EPS. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, equities research analysts forecast that Progyny, Inc. will post 1.25 earnings per share for the current fiscal year.

Progyny announced that its board has approved a stock buyback program on Tuesday, May 26th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to repurchase up to 10.3% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

PGNY has been the subject of several recent research reports. Truist Financial raised their target price on shares of Progyny from $33.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Canaccord Genuity Group set a $35.00 price objective on shares of Progyny in a research note on Friday, August 7th. Wells Fargo & Company started coverage on Progyny in a research report on Thursday, August 20th. They set an “overweight” rating and a $37.00 price objective for the company. Barclays reduced their target price on Progyny from $34.00 to $30.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 12th. Finally, Citigroup reiterated a “market outperform” rating on shares of Progyny in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Progyny currently has an average rating of “Moderate Buy” and a consensus price target of $33.91.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.